Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.1.041

Prostate Stem Cell Antigen Single Nucleotide Polymorphisms Influence Risk of Estrogen Receptor Negative Breast Cancer in Korean Females  

Kim, Sook-Young (Cancer Genomics Branch, National Cancer Center)
Yoo, Jae-Young (Cancer Genomics Branch, National Cancer Center)
Shin, Ae-Sun (Molecular Epidemiology Branch, National Cancer Center)
Kim, Yeon-Ju (Cancer Early Detection Branch, National Cancer Center)
Lee, Eun-Sook (Convergence Technology Division, National Cancer Center)
Lee, Yeon-Su (Cancer Genomics Branch, National Cancer Center)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.1, 2012 , pp. 41-48 More about this Journal
Abstract
Introduction: Breast cancer is the second leading cancer in Korean women. To assess potential genetic associations between the prostate stem cell antigen (PSCA) gene in the chromosome 8q24 locus and breast cancer risk in Korean women, 13 SNPs were selected and associations with breast cancer risk were analyzed with reference to hormone receptor (HR) and menopausal status. Methods:We analyzed DNA extracted from buffy coat from 456 patients and 461 control samples, using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) based upon region-specific PCR followed by allelespecific single base primer extension reactions. Risks associated with PSCA genotypes and haplotypes were estimated with chi-square test (${\chi}^2$-test), and polytomous logistic regression models using odds ratios (OR) and 95% confidence intervals (CIs), by HR and menopausal status. Results: In case-control analysis, odds ratios (OR) of rs2294009, rs2294008, rs2978981, rs2920298, rs2976395, and rs2976396 were statistically significant only among women with estrogen receptor (ER) negative cancers, and those of rs2294008, rs2978981, rs2294010, rs2920298, rs2976394, rs10216533, and rs2976396 were statistically significant only in pre-menopausal women, and not in postmenopausal women. Risk with the TTGGCAA haplotype was significantly elevated in ER (-) status (OR= 1.48, 95% CI= 1.03~2.12, p<0.05). Especially risk of allele T of rs2294008 is significantly low in pre-menopausal breast cancer patients and AA genotype of rs2976395 in ER (-) status represents the increase of OR value. Conclusion: This report indicated for the first time that associations exist between PSCA SNPs and breast cancer susceptibility in Korean women, particularly those who are pre-menopausal with an estrogen receptor negative tumor status.
Keywords
PSCA; breast cancer; 8q24; polymorphism; biomarker;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Wiechec E, Hansen LL (2009). The effect of genetic variability on drug response in conventional breast cancer treatment. Eur J Pharmacol, 625, 122-30.   DOI
2 Williams C, Brunskill S, Altman D, et al. (2006). Costeffectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess, 10, iii-iv, ix-xi, 1-204.
3 Wu X, Ye Y, Kiemeney LA, et al. (2009). Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet, 41, 991-5.   DOI
4 Yang X, Lippman ME (1999). BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat, 54, 1-10.   DOI
5 Yeager M, Xiao N, Hayes RB, et al. (2008). Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Hum Genet, 124, 161-70.   DOI
6 Offit K, Robson ME (2010). New pharmacogenomic paradigm in breast cancer treatment. J Clin Oncol, 28, 4665-6.   DOI
7 Onay VU, Briollais L, Knight JA, et al. (2006). SNP-SNP interactions in breast cancer susceptibility. BMC Cancer, 6, 114.   DOI
8 Orlando L, Schiavone P, Fedele P, et al. (2010). Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev, 36 Suppl 3, S67-71.   DOI
9 Ozet A, Yavuz AA, Komurcu S, et al. (2000). Bilateral male breast cancer and prostate cancer: a case report. Jpn J Clin Oncol, 30, 188-90.   DOI
10 Raff AB, Gray A, Kast WM (2009). Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett, 277, 126-32.   DOI
11 Reiter RE, Gu Z, Watabe T, et al. (1998). Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A, 95, 1735-40.   DOI
12 Rochefort H, Glondu M, Sahla ME, et al. (2003). How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer, 10, 261-6.   DOI
13 Thomas G, Jacobs KB, Kraft P, et al. (2009). A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet, 41, 579-84.   DOI
14 Rugo HS (2008). The breast cancer continuum in hormonereceptor- positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol, 19, 16-27.   DOI
15 Sakamoto H, Yoshimura K, Saeki N, et al (2008). Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet, 40, 730-40.   DOI
16 Smith LF (2007). Palpable cancer of the breast and negative mammography: the ongoing dilemma. J Surg Oncol, 96, 451-2.   DOI
17 Uray IP, Brown PH (2011). Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res, 188, 147-62.
18 Garcia-Closas M, Chanock S (2008). Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res, 14, 8000-9.   DOI
19 Gluz O, Liedtke C, Gottschalk N, et al. (2009). Triple-negative breast cancer--current status and future directions. Ann Oncol, 20, 1913-27.   DOI
20 Habel LA, Capra AM, Oestreicher N, et al. (2007). Mammographic density in a multiethnic cohort. Menopause, 14, 891-9.   DOI
21 Han JS, Cao D, Molberg KH, et al. (2011). Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triplenegative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triplenegative breast carcinomas. Am J Clin Pathol, 135, 230-7.   DOI
22 Imyanitov EN (2009). Gene polymorphisms, apoptotic capacity and cancer risk. Hum Genet, 125, 239-46.   DOI
23 Lopez-Otin C, Diamandis EP (1998). Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev, 19, 365-96.   DOI
24 Jung KW, Park S, Kong HJ, et al. (2011). Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat, 43, 1-11.   DOI
25 Kim BK, Lee JW, Park PJ, et al. (2009). The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res, 11, R22.   DOI
26 Li J, Humphreys K, Heikkinen T, et al. (2010). A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat.
27 Matera L (2010). The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev, 36, 131-41.   DOI
28 Matsuo K, Tajima K, Suzuki T, et al. (2009). Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese. Int J Cancer, 125, 1961-4.   DOI
29 Berndt SI, Potter JD, Hazra A, et al. (2008). Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk. Hum Mol Genet, 17, 2665-72.   DOI
30 Buck MB, Fritz P, Dippon J, et al. (2004). Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res, 10, 491-8.   DOI
31 Chen JQ, Brown TR, Russo J (2009). Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta, 1793, 1128-43.   DOI
32 Chu LW, Meyer TE, Li Q, et al. (2010). Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin. Cancer Epidemiol Biomarkers Prev, 19, 1848- 54.   DOI
33 Cianfrocca M, Gradishar W (2009). New molecular classifications of breast cancer. CA Cancer J Clin, 59, 303-13.   DOI
34 Coffey DS (2001). Similarities of prostate and breast cancer: Evolution, diet, and estrogens. Urology, 57, 31-8.   DOI
35 Czajka-Oraniec I, Simpson ER (2010). Aromatase research and its clinical significance. Endokrynol Pol, 61, 126-34.
36 Ferlay J, Shin HR, Bray F, et al. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917.   DOI
37 Fletcher O, Johnson N, Gibson L, et al. (2008). Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol Biomarkers Prev, 17, 702-5.   DOI
38 Frasor J, Danes JM, Komm B, et al. (2003). Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology, 144, 4562-74.   DOI
39 AleAhmad S, Casey G, Sweeney P, et al (2009). Prostate stem cell antigen DNA vaccination breaks tolerance to selfantigen and inhibits prostate cancer growth. Mol Ther, 17, 1101-8.   DOI
40 Ahn SH (2004). Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg, 139, 27-30, discussion 1.   DOI
41 Benson JR, Jatoi I, Keisch M, et al. (2009). Early breast cancer. Lancet, 373, 1463-79.   DOI